229 related articles for article (PubMed ID: 36244677)
1. Letermovir as Cytomegalovirus Prophylaxis in a Pediatric Cohort: A Retrospective Analysis.
Kuhn A; Puttkammer J; Madigan T; Dinnes L; Khan S; Ferdjallah A; Kohorst M
Transplant Cell Ther; 2023 Jan; 29(1):62.e1-62.e4. PubMed ID: 36244677
[TBL] [Abstract][Full Text] [Related]
2. Extended duration letermovir in allogeneic hematopoietic stem cell transplant.
Hinman B; Cox J; Umoru G; Kamble R; Musick W
Transpl Immunol; 2023 Dec; 81():101936. PubMed ID: 37770000
[TBL] [Abstract][Full Text] [Related]
3. Letermovir Prophylaxis for Cytomegalovirus Infection in Children After Hematopoietic Cell Transplantation.
Richert-Przygonska M; Jaremek K; Debski R; Konieczek J; Lecka M; Dziedzic M; Bogiel T; Styczynski J; Czyzewski K
Anticancer Res; 2022 Jul; 42(7):3607-3612. PubMed ID: 35790275
[TBL] [Abstract][Full Text] [Related]
4. Real world experience: Examining outcomes using letermovir for CMV prophylaxis in high-risk allogeneic hematopoietic stem cell patients in the setting of using T-cell depletion as GVHD prophylaxis.
Dwabe S; Hsiao M; Ali A; Rodman J; Savitala-Damerla L; Nazaretyan S; Kimberly Schiff NP; Tam E; Ladha A; Woan K; Chaudhary P; Yaghmour G
Transpl Immunol; 2023 Feb; 76():101769. PubMed ID: 36464218
[TBL] [Abstract][Full Text] [Related]
5. Letermovir for Cytomegalovirus infection in pediatric patients undergoing allogenic hematopoietic stem cell transplantation: a real-life study by the Infectious Diseases Working Group of Italian Association of Pediatric Hematology-Oncology (AIEOP).
Galaverna F; Baccelli F; Zama D; Tridello G; Masetti R; Soncini E; Mura R; Barzaghi F; Colombini A; Prunotto G; D'Amico MR; Calore E; Biffi A; Perruccio K; Gasperini P; Oltolini C; Quagliarella F; Giacomazzi A; Pagliara D; Locatelli F; Cesaro S
Bone Marrow Transplant; 2024 Apr; 59(4):505-512. PubMed ID: 38272999
[TBL] [Abstract][Full Text] [Related]
6. Letermovir for Prophylaxis and Pre-emptive Therapy of Cytomegalovirus Infection in Paediatric Allogeneic Haematopoietic Cell Transplant Patients.
Körholz KF; Füller MA; Hennies M; Holterhus M; Hagedorn S; Ahlmann M; Thorer H; Burkhardt B; Groll AH
Paediatr Drugs; 2023 Mar; 25(2):225-232. PubMed ID: 36572834
[TBL] [Abstract][Full Text] [Related]
7. Letermovir for Secondary Prophylaxis of Cytomegalovirus Infection and Disease after Allogeneic Hematopoietic Cell Transplantation: Results from the French Compassionate Program.
Robin C; Thiebaut A; Alain S; Sicre de Fontbrune F; Berceanu A; D'Aveni M; Ceballos P; Redjoul R; Nguyen-Quoc S; Bénard N; Pahlavan-Grumel G; Cordonnier C
Biol Blood Marrow Transplant; 2020 May; 26(5):978-984. PubMed ID: 32035273
[TBL] [Abstract][Full Text] [Related]
8. Letermovir for primary and secondary cytomegalovirus prevention in allogeneic hematopoietic cell transplant recipients: Real-world experience.
Lin A; Maloy M; Su Y; Bhatt V; DeRespiris L; Griffin M; Lau C; Proli A; Barker J; Shaffer B; Giralt SA; Jakubowski AA; Papadopoulos EB; Papanicolaou GA; Seo SK; Perales MA
Transpl Infect Dis; 2019 Dec; 21(6):e13187. PubMed ID: 31585500
[TBL] [Abstract][Full Text] [Related]
9. Cytomegalovirus events in high-risk allogeneic hematopoietic-cell transplantation patients who received letermovir prophylaxis.
Chen K; Arbona-Haddad E; Cheng MP; McDonnell AM; Gooptu M; Orejas JL; Timblin K; Silverman E; Al-Hamed R; Soiffer RJ; Hammond SP; Marty FM
Transpl Infect Dis; 2021 Aug; 23(4):e13619. PubMed ID: 33866648
[TBL] [Abstract][Full Text] [Related]
10. Letermovir conversion after valganciclovir treatment in cytomegalovirus high-risk abdominal solid organ transplant recipients may promote development of cytomegalovirus-specific cell mediated immunity.
Jorgenson MR; Kleiboeker H; Garg N; Parajuli S; Mandelbrot DA; Odorico JS; Saddler CM; Smith JA
Transpl Infect Dis; 2022 Feb; 24(1):e13766. PubMed ID: 34799964
[TBL] [Abstract][Full Text] [Related]
11. Single-center experience with use of letermovir for CMV prophylaxis or treatment in thoracic organ transplant recipients.
Aryal S; Katugaha SB; Cochrane A; Brown AW; Nathan SD; Shlobin OA; Ahmad K; Marinak L; Chun J; Fregoso M; Desai S; King C
Transpl Infect Dis; 2019 Dec; 21(6):e13166. PubMed ID: 31487755
[TBL] [Abstract][Full Text] [Related]
12. Real-Life Data on the Efficacy and Safety of Letermovir for Primary Prophylaxis of Cytomegalovirus in Allogeneic Hematopoietic Stem Cell Recipients: A Single-Center Analysis.
Włodarczyk M; Wieczorkiewicz-Kabut A; Białas K; Koclęga A; Noster I; Zielińska P; Helbig G
Turk J Haematol; 2024 Mar; 41(1):9-15. PubMed ID: 38345092
[TBL] [Abstract][Full Text] [Related]
13. Letermovir vs Valganciclovir for Prophylaxis of Cytomegalovirus in High-Risk Kidney Transplant Recipients: A Randomized Clinical Trial.
Limaye AP; Budde K; Humar A; Vincenti F; Kuypers DRJ; Carroll RP; Stauffer N; Murata Y; Strizki JM; Teal VL; Gilbert CL; Haber BA
JAMA; 2023 Jul; 330(1):33-42. PubMed ID: 37279999
[TBL] [Abstract][Full Text] [Related]
14. Clinical "real-world" experience with letermovir for prevention of cytomegalovirus infection in allogeneic hematopoietic cell transplant recipients.
Anderson A; Raja M; Vazquez N; Morris M; Komanduri K; Camargo J
Clin Transplant; 2020 Jul; 34(7):e13866. PubMed ID: 32242979
[TBL] [Abstract][Full Text] [Related]
15. Real-life use of letermovir prophylaxis for cytomegalovirus in heart transplant recipients.
Saltiel G; Faure E; Assaf A; Chopin MC; Moreau F; Faure K; Goeminne C; Vuotto F
Clin Transplant; 2024 May; 38(5):e15327. PubMed ID: 38686437
[TBL] [Abstract][Full Text] [Related]
16. Use of Letermovir for Primary and Secondary Cytomegalovirus Prophylaxis in Abdominal Organ Transplantation: A Single Center Experience.
Ibrahim D; Byrns J; Maziarz E; Alexander BD; Saullo JL
J Pharm Pract; 2024 Jun; 37(3):770-779. PubMed ID: 37280011
[No Abstract] [Full Text] [Related]
17. Letermovir for Cytomegalovirus prophylaxis in pediatric hematopoietic stem cell transplantation.
Chen TT; David AP; Barthelmess EK; MacBrayne CE
Pediatr Blood Cancer; 2023 Nov; 70(11):e30608. PubMed ID: 37548491
[TBL] [Abstract][Full Text] [Related]
18. Fast breakthrough of resistant cytomegalovirus during secondary letermovir prophylaxis in a hematopoietic stem cell transplant recipient.
Jung S; Michel M; Stamminger T; Michel D
BMC Infect Dis; 2019 May; 19(1):388. PubMed ID: 31068147
[TBL] [Abstract][Full Text] [Related]
19. Pharmacokinetic analysis driven letermovir dosing in pediatric hematopoietic cell transplantation patients with resistant CMV disease.
Pai VB; Tansmore J; Song E
Pediatr Transplant; 2024 Feb; 28(1):e14580. PubMed ID: 37466088
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics, Safety, and Efficacy of Letermovir for Cytomegalovirus Prophylaxis in Adolescent Hematopoietic Cell Transplantation Recipients.
Groll AH; Schulte JH; Antmen AB; Fraser CJ; Teal VL; Haber B; Caro L; McCrea JB; Fancourt C; Patel M; Menzel K; Badshah C
Pediatr Infect Dis J; 2024 Mar; 43(3):203-208. PubMed ID: 38241643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
